spacer
home > ebr > spring 2017 > managing e&l unknown compounds
PUBLICATIONS
European Biopharmaceutical Review

Managing E&L Unknown Compounds

Unknown compound characterisation has always been one of the most challenging aspects of analytical chemistry. Despite the difficulties, this identification is critical for a meaningful extractables and leachables (E&L) evaluation of container closure systems; single-use systems; drug delivery and combination products; and medical devices.

Identification of unknown extractable compounds is key to a successful E&L study due to the fact that there is no universally established concentration limit for leachable compounds. As a result, a toxicological risk assessment based on the intended dosing regimen of the product is required to determine if a potential leachable compound poses a risk to patient safety. Unfortunately, accurate and meaningful toxicological assessments are not possible for unknown compounds. These are typically assessed using a worst case scenario, where they are evaluated as extremely toxic – this however often leads to applying an inaccurate level of risk. Therefore, a systematic approach for the characterisation of unknown extractable compounds is essential to enable scientists to assign the correct degree of toxicological concern to a given analyte.

So, how does one go about identifying an unknown compound? The use of the proper instrumentation is critical. High resolution mass spectrometers that enable an accurate mass determination to at least three decimal places – such as liquid chromatographyquadrupole time of flights (LC-QTOFs) and gas chromatography (GC)-QTOFs – are suitable for this purpose and their use generates a plethora of data that can often lead to the identification of an empirical formula or class of compound for the unknown. This information can then be further evaluated with specialised software that is able to quickly search historical data and databases to provide a preliminary identification of the unknown extractable compound.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Simone Carrara, E&L Laboratory Manager; Andrew Blakinger, Manager, Extractables & Leachables Testing; Thomas Lehman, PhD, Director, Method Development and Validation and Extractables and Leachables, Eurofins BioPharma Product Testing
spacer
Simone Carrara
spacer
spacer
spacer
Andrew Blakinger
spacer
spacer
spacer
Thomas Lehman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck to Provide Provantage® End-to-End Services to Acticor Biotech SAS


More info >>

White Papers

Case Study: Emerade® Auto-Injector

SHL Group

The Emerade® Auto Injector is an intuitive disposable 2-step auto injector designed to deliver adrenaline via intramuscular injection during emergency use. The exterior of the device has a simple and sleek industrial design with the aim to minimize confusion for users. To achieve the penetration force required for an intramuscular injection while still ensuring the dosage is delivered correctly and needle protection mechanisms are in place, the Emerade Auto Injector is equipped with an advanced 3 spring technology. The device is also available in 3 doses (150mcg, 300mcg, 500mcg), with each recommended for patients of different bodyweights to maximize efficacy.
More info >>

 
Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement